ATE165010T1 - Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen - Google Patents

Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen

Info

Publication number
ATE165010T1
ATE165010T1 AT89101295T AT89101295T ATE165010T1 AT E165010 T1 ATE165010 T1 AT E165010T1 AT 89101295 T AT89101295 T AT 89101295T AT 89101295 T AT89101295 T AT 89101295T AT E165010 T1 ATE165010 T1 AT E165010T1
Authority
AT
Austria
Prior art keywords
purification
beta2
human ifn
ifn
beta
Prior art date
Application number
AT89101295T
Other languages
English (en)
Inventor
Michel Revel
Menachem Rubinstein
Yves Mory
Louise Chen
Daniela Novick
Rita Michalevicz
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL85204A external-priority patent/IL85204A0/xx
Priority claimed from IL88376A external-priority patent/IL88376A0/xx
Priority claimed from IL8837588A external-priority patent/IL88375A/en
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE165010T1 publication Critical patent/ATE165010T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • External Artificial Organs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT89101295T 1988-01-26 1989-01-25 Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen ATE165010T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL85204A IL85204A0 (en) 1988-01-26 1988-01-26 Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it
US19358088A 1988-05-13 1988-05-13
IL88376A IL88376A0 (en) 1988-11-14 1988-11-14 Pharmaceutical compositions containing interferon-beta 2
IL8837588A IL88375A (en) 1988-11-14 1988-11-14 Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method

Publications (1)

Publication Number Publication Date
ATE165010T1 true ATE165010T1 (de) 1998-05-15

Family

ID=27452320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89101295T ATE165010T1 (de) 1988-01-26 1989-01-25 Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen

Country Status (7)

Country Link
EP (1) EP0326120B1 (de)
JP (1) JP2725818B2 (de)
AT (1) ATE165010T1 (de)
AU (1) AU621852B2 (de)
CA (1) CA1341588C (de)
DE (1) DE68928641T2 (de)
ES (1) ES2119735T3 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006370A1 (en) * 1988-12-01 1990-06-14 The Trustees Of The University Of North Carolina Synthetic interleukin-6
JPH0331215A (ja) * 1989-06-27 1991-02-12 Ajinomoto Co Inc 制癌療法支持剤
DE3939706C1 (de) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
DK0504307T3 (da) * 1989-12-04 1994-03-21 Schering Corp Fremgangsmåde til behandling af septisk shock
IT1247484B (it) * 1991-03-22 1994-12-17 Ceinge Societa Consortile A R Metodo per la preparazione di interleuchina 6
US5902576A (en) * 1992-10-22 1999-05-11 Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science Antitumor pharmaceutical composition comprising IL-6 transfected cells
WO1996025433A1 (en) * 1995-02-15 1996-08-22 Mount Sinai School Of Medicine Of The City University Of New York B cell differentiation and proliferation factors and methods for obtaining and using the same
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
EP1489100B1 (de) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimäre Fusionsproteine zur Verwendung für gezielte Immuntherapie und allgemeine Immunerregung
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
EP1228214A2 (de) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietinformen mit verbesserten eigenschaften
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP2336181A1 (de) * 2005-12-09 2011-06-22 UCB Pharma, S.A. Antikörpermoleküle mit menschlicher IL-6-Spezifizität
BRPI0620648B1 (pt) 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
EP2421896A1 (de) 2009-04-22 2012-02-29 Merck Patent GmbH Antikörperfusionsproteine mit modifizierten fcrn-bindungsstellen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172496A (ja) * 1983-03-18 1984-09-29 Kyowa Hakko Kogyo Co Ltd モノクロ−ナル抗体
JPH0657157B2 (ja) * 1984-11-09 1994-08-03 忠三 岸本 Ｂ細胞分化因子の製造法
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US5198359A (en) * 1989-03-07 1993-03-30 Boehringer Ingelheim International Gmbh Recombinant protein receptor for il-2

Also Published As

Publication number Publication date
JP2725818B2 (ja) 1998-03-11
DE68928641T2 (de) 1998-08-13
ES2119735T3 (es) 1998-10-16
AU2881389A (en) 1989-07-27
EP0326120A3 (de) 1990-05-02
DE68928641D1 (de) 1998-05-20
CA1341588C (en) 2009-01-06
AU621852B2 (en) 1992-03-26
JPH029394A (ja) 1990-01-12
EP0326120A2 (de) 1989-08-02
EP0326120B1 (de) 1998-04-15

Similar Documents

Publication Publication Date Title
ATE165010T1 (de) Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen
PH25120A (en) Replicable expression vehicle and process of preparation thereof
NO176665C (no) Fremgangsmåte for fremstilling av ikke-glykosylert IL-6 og vektor for utskillelse derav
DE69131699D1 (de) Verändertes menschliches iL-6
ATE166232T1 (de) Interleukin 2 enthaltende rekombinante immunkonjugate für die therapie
EP0759067A4 (de) Transformierender wachstumsfaktor alpha h1
FI885807L (fi) Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen
DE69233143D1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
DE68928710D1 (de) T-Zellen-Wachstumsfaktor
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
FI922770A0 (fi) Bcrf1-proteinerna som inhibitorer av y-interferon.
HUT59724A (en) Process for producing new thrombosolving material
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
EP0516845A4 (de) Neuer megakaryokytischer koloniestimulierender faktor und verfahren zur herstellung.
EP0672684A4 (de) Neuer megakaryot-kolonie-stimulierender faktor und seine herstellung.
JPS6452792A (en) Production of blood platelet growth factor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time